{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:12:32Z","timestamp":1791141152371,"version":"4.1.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,2,1]],"date-time":"2003-02-01T00:00:00Z","timestamp":1044057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2003,2]]},"DOI":"10.1016\/s0248-8663(02)00022-x","type":"journal-article","created":{"date-parts":[[2003,3,25]],"date-time":"2003-03-25T18:24:25Z","timestamp":1048616665000},"page":"123-126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Les inhibiteurs du TNF\u03b1"],"prefix":"10.1016","volume":"24","author":[{"given":"C.","family":"Brousse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/S0248-8663(02)00022-X_BIB1","first-page":"660","article-title":"Twelwe weeks clinical and radiologic results from the ATTRACT trial: a 2 years randomized, controlled, phase 3 trial of infliximab in patients with active RA despite methotrexate","volume":"43","author":"Lipsky","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB2","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric antitumor necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concommitant methotrexate: a randomized phase III trial, ATTRACT study group","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1056\/NEJM199901283400401","article-title":"A trial of etanercept a recombinant tumor necrosis factor receptor Fc fusion protein in patients with rheumatoid arthritis receiving methotrexate","volume":"340","author":"Weinblatt","year":"1999","journal-title":"N Engl J M"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB4","doi-asserted-by":"crossref","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","article-title":"Etanercept therapy in rheumatoid arthritis. A randomized, contrelled trial","volume":"130","author":"Moreland","year":"1999","journal-title":"Ann Intern M"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB5","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N Engl J M"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenil rheumatoid arthritis","volume":"342","author":"Lowell","year":"2000","journal-title":"N Engl J M"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB7","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor neutralising agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J M"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/1529-0131(200109)44:9<1977::AID-ART345>3.0.CO;2-6","article-title":"Demyelininating and neurologic events reported in associated with tumor necrosis factor antagonism, By wat mechanism could tumor necrosis factor antagonist improve rheumatoid arthritis but exacerbate multiple sclerosis?","volume":"44","author":"Robinson","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB9","first-page":"959","article-title":"Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety","volume":"29","author":"Maksymowych","year":"2002","journal-title":"J Rheum"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriasis arthritis and psoriasis: a randomized trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB11","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/1529-0131(200110)44:10<2371::AID-ART401>3.0.CO;2-W","article-title":"Infliximab in patients with primary Sj\u00f6gren syndrome. A pilot study","volume":"44","author":"Steinfield","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/S0248-8663(02)00022-X_BIB12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1046\/j.1365-2230.2001.00753.x","article-title":"Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate","volume":"26","author":"Kirby","year":"2001","journal-title":"Clin Exp Dermatol"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886630200022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S024886630200022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:06:19Z","timestamp":1759334779000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S024886630200022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2003,2]]}},"alternative-id":["S024886630200022X"],"URL":"https:\/\/doi.org\/10.1016\/s0248-8663(02)00022-x","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2003,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les inhibiteurs du TNF\u03b1","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/S0248-8663(02)00022-X","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 \u00c9ditions scientifiques et m\u00e9dicales Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}